HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases.

Abstract
Various foods are associated with effects against metabolic diseases such as insulin resistance and type 2 diabetes; however, their mechanisms of action are mostly unclear. Fatty acids may contribute by acting as precursors of signalling molecules or by direct activity on receptors. The medium- and long-chain NEFA receptor FFA1 (free fatty acid receptor 1, previously known as GPR40) has been linked to enhancement of glucose-stimulated insulin secretion, whereas FFA4 (free fatty acid receptor 4, previously known as GPR120) has been associated with insulin-sensitising and anti-inflammatory effects, and both receptors are reported to protect pancreatic islets and promote secretion of appetite and glucose-regulating hormones. Hypothesising that FFA1 and FFA4 mediate therapeutic effects of dietary components, we screened a broad selection of NEFA on FFA1 and FFA4 and characterised active compounds in concentration-response curves. Of the screened compounds, pinolenic acid, a constituent of pine nut oil, was identified as a relatively potent and efficacious dual FFA1/FFA4 agonist, and its suitability for further studies was confirmed by additional in vitro characterisation. Pine nut oil and free and esterified pure pinolenic acid were tested in an acute glucose tolerance test in mice. Pine nut oil showed a moderately but significantly improved glucose tolerance compared with maize oil. Pure pinolenic acid or ethyl ester gave robust and highly significant improvements of glucose tolerance. In conclusion, the present results indicate that pinolenic acid is a comparatively potent and efficacious dual FFA1/FFA4 agonist that exerts antidiabetic effects in an acute mouse model. The compound thus deserves attention as a potential active dietary ingredient to prevent or counteract metabolic diseases.
AuthorsElisabeth Christiansen, Kenneth R Watterson, Claire J Stocker, Elena Sokol, Laura Jenkins, Katharina Simon, Manuel Grundmann, Rasmus K Petersen, Edward T Wargent, Brian D Hudson, Evi Kostenis, Christer S Ejsing, Michael A Cawthorne, Graeme Milligan, Trond Ulven
JournalThe British journal of nutrition (Br J Nutr) Vol. 113 Issue 11 Pg. 1677-88 (Jun 14 2015) ISSN: 1475-2662 [Electronic] England
PMID25916176 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Dietary Fats
  • FFAR4 protein, mouse
  • Ffar1 protein, mouse
  • Insulin
  • Linolenic Acids
  • Receptors, G-Protein-Coupled
  • 5,9,12-octadecatrienoic acid
Topics
  • Animals
  • Diabetes Mellitus, Type 2 (prevention & control)
  • Dietary Fats (pharmacology)
  • Disease Models, Animal
  • Glucose Tolerance Test
  • HEK293 Cells
  • Humans
  • Insulin (blood, metabolism)
  • Insulin Resistance
  • Insulin Secretion
  • Islets of Langerhans (drug effects, metabolism)
  • Linolenic Acids (pharmacology)
  • Male
  • Metabolic Syndrome (prevention & control)
  • Mice
  • Mice, Inbred C57BL
  • Nuts (chemistry)
  • Pinus
  • Receptors, G-Protein-Coupled (agonists, genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: